Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Borraginol EP
- Development stage
- Unknown
- Lead developer
- Amato Pharmaceutical Products
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Borraginol EP (marketed as BORRAGINOL® EP ORAL) is an approved Category 2 over-the-counter (OTC) oral antihemorrhoidal medication developed and marketed by Amato Pharmaceutical Products in Japan. Formulated as readily soluble granules in convenient stick-type packets, it is taken orally twice a day. The active ingredients consist of three herbal drug extracts—Moutan cortex extract (peony root bark), Rosskastanien extract (horse chestnut seed), and Lithospermi radix aqueous extract (purple root)—along with vitamin E acetate (tocopherol acetate). Borraginol EP works from the inside out by improving blood circulation in the anorectal region and suppressing inflammation, thereby addressing the underlying circulatory and inflammatory mechanisms of hemorrhoids. It is indicated for the relief of symptoms such as pain, bleeding, swelling, and itching due to hemorrhoids (including internal/blind piles and bleeding hemorrhoids) and anal fissures.
- Brand names
- Borraginol EPBORRAGINOL EP ORAL
- Other names
- Oral Borraginol EP内服ボラギノールEP
Beyond the preview
Go deeper on Borraginol EP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Borraginol EP.